Abiopharma

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Jushi Holdings Inc. Reports Third Quarter 2025 Financial Results